Invention Grant
- Patent Title: Substituted pyrimidines as LRKK2 inhibitors
-
Application No.: US16083438Application Date: 2017-03-10
-
Publication No.: US11028080B2Publication Date: 2021-06-08
- Inventor: Anthony A. Estrada , Jianwen A. Feng , Joseph P. Lyssikatos , Zachary K. Sweeney , Javier de Vicente Fidalgo
- Applicant: Denali Therapeutics Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Denali Therapeutics Inc.
- Current Assignee: Denali Therapeutics Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Rothwell, Figg, Ernst & Manbeck, P.C.
- International Application: PCT/US2017/021964 WO 20170310
- International Announcement: WO2017/156493 WO 20170914
- Main IPC: A61K31/506
- IPC: A61K31/506 ; C07D239/42 ; C07D417/12 ; C07D417/14 ; C07D403/14 ; C07D403/12 ; C07D498/08

Abstract:
The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
Public/Granted literature
- US20190084975A1 COMPOUNDS, COMPOSITIONS, AND METHODS Public/Granted day:2019-03-21
Information query
IPC分类: